

Use of non-steroidal anti-inflammatory drugs in the prevention of Alzheimer's disease in the high risk patient.

Qinglu (Chinglu) Li, B.Sc.

Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, B3H 4H7

Alzheimer's disease (AD) is a major neurological disorder causing dementia in the elderly. Because the causes of AD are not known, there is no real treatment for this disorder. However, a number of risk factors have been associated with AD. Among these factors, a family history of AD is most significant. An inverse association between non-steroidal anti-inflammatory drugs (NSAIDs) use and AD has been previously demonstrated in several epidemiological studies. Here the potential use of NSAIDs as a protective measure for individuals in high risk groups is suggested.

INTRODUCTION

Dementia is an age-related disorder. It has become a major health problem because of the worldwide increase in the elderly population, especially those 80 years of age or older. This increase in the elderly population presents a serious health problem for Canadians. According to the 1991 census 13.8% (3,157,500) of the Canadian population are aged 65 and over (1). Among this population, the prevalence of dementia was estimated to be 8.0% (252,600) (2). It was suggested that if the prevalence estimated remains constant, the number of Canadians with dementia will rise to 592,000 by the year 2021(2).

Failure to learn and loss of analytical ability are the neurological signs of dementia. Patients are alert and attentive to a given task but fail because of memory deficits. Due to these neurological dysfunctions, people with dementia lose the ability to work and to manage their daily lives.

Many different conditions have been associated with dementia. The most prevalent causes of dementia are Alzheimer's disease (AD) and vascular dementia (3). In the Rotterdam study (4), AD accounts for about three quarters of

all cases of dementia. There is at present no treatment for AD, although nerve growth factor and cholinergic analogs have been used in attempt to reduce the cholinergic neuronal death and to restore cholinergic function. Present interventions are mainly aimed at maintaining skills and reducing behavioural disturbance by using programmes including cognitive training or environmental redesign as well as caregiver training (5).

Although the causes and the mechanisms of AD are still unknown, a great amount of work has been devoted to identifying major risk factors associated with AD. As discussed below, epidemiological studies, as well as genetic studies, have demonstrated that certain conditions could predispose individuals to AD (6-9). Recent case-control and population based studies (10, 11) suggest the potential use of anti-inflammatory drugs in the prevention of AD. Due to the lack of treatment for AD, possible prevention or delaying development of AD will provide hope for individuals in high risk groups.

In this paper, the risk factors associated with AD will be presented. The potential of NSAIDs in preventing AD in high risk individuals will be discussed.

RISK FACTORS OF AD

Both genetic and epigenetic factors have been suggested to be risk factors associated with the development of AD.

Address correspondence to:

Chinglu Li, Box 141, Sir Charles Tupper Medical Building, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7

1. Genetic hypothesis

There is now strong evidence for the association of genetic factors with AD. The tendency of clustering of AD patients among close relatives has been reported in many studies (8, 9). Case-control studies have shown a significant association between the presence of dementia among first-degree relatives and AD (12). Not all AD patients, however, had such familial aggregation. Nevertheless, patients with an earlier age onset of AD are more likely to have relatives with AD than are patients with a later age onset of the disease (13). It has been suggested that an onset of age 70 be used to differentiate individuals whose relatives were at higher risk from those whose relatives were at lower risk (13).

Three genetic loci have now been identified that predispose to AD: AD1 on chromosome 21, AD2 on chromosome 19 and AD3 on chromosome 14 (14). A small percentage of individuals suffering from familial AD are known to possess mutations in the gene encoding a protein known as the amyloid protein precursor or APP. These mutations are autosomal dominant and are localized on chromosome 21 (15). It has long been recognized that another genetic abnormality, Down syndrome (trisomy 21), is closely associated with early and severe development of AD neuropathology (16). A larger percentage of patients with familial AD are found to have a specific locus on chromosome 14 (7). This gene has recently been identified and it encodes a protein with multiple putative transmembrane domains. However, the physiological function of this protein is not yet known.

The majority of AD is non-familial and is of late-onset or sporadic form. It is now recognized that possession of one or two copies of the E4 allele of the apolipoprotein E gene, which is located on chromosome 19, is a risk factor for this form of AD (17, 18). However, it should be noted, however, that the apolipoprotein E gene is not a disease locus (i.e. specific mutations in this gene do not cause AD).

The association of apolipoprotein E gene with AD has been challenged by one study (19). In this study, the prevalence of apolipoprotein E gene was examined in both AD and non-AD dementia patients. The results suggested that the E4 allele of the apolipoprotein E gene is not unique to AD and that the importance of this gene as a risk factor for AD should therefore be reconsidered.

2. Environmental risk factors

Genetic factors alone cannot account for all cases of AD. Environmental risk factors may also play a major role. There is evidence that head trauma could be a contributory factor. An history of head injury was found in 20% of the familial AD and 43.5% of sporadic AD cases compared to only 2.9% in control group (20). Based on these results, the authors hypothesized that head injury was more common among AD patients without a genetic risk for the disease (20). On the other hand, se-

vere headache and smoking have an inverse relationship with AD (21, 22).

Although aluminum toxicity has not been ruled out as a contributory factor, there is little evidence for a causal link. Experimental studies have demonstrated an aluminum-induced chronic myelopathy in rabbits and the development of neurofilamentous lesions after low-dose aluminum administration in cell culture (23). Other evidence in support of aluminum as a risk factor for AD has been inconsistent (24-27).

Recently, studies have shown an inverse relationship between levels of education and the prevalence of dementia and AD. In a survey in China, the prevalence of both dementia and AD decreased from 6.9% in illiterate persons to 1.2% in those with over 6 years of education (28). Similar results have been reported in other studies (4, 29, 30, 33). Katzman hypothesized that education can result in decreased risk of AD (31). However, this hypothesis has not received full support. Cobb *et al.* (32) suggested that while incidence rates were significantly elevated for AD and non-AD dementia among the least educated, low educational attainment, after age adjustment, was not a significant risk factor for the incidence of general dementia or of AD.

Some retrospective studies have reported an association of Parkinson's Disease (PD) with AD (34). A recent prospective cohort study concluded that patients with PD, especially those with severe extrapyramidal signs, have twice the risk for the development of dementia than control subjects (35).

3. Other risk factors

A history of depression and other psychiatric disorders has been suggested as a risk factor for dementia, especially for AD (54). It is generally accepted that the age-specific incidence of AD is higher in females than in males. Hypothyroidism has also been suggested as a strong risk factor for AD (55).

On the other hand, rheumatoid arthritis (9) and smoking (22) seem to reduce the risk of developing AD. It is possible that the decreased risk of AD among smokers might be due to the potential action of cigarette nicotine on nicotinic receptors in the central nervous system (36, 37). The inverse relationship of arthritis and AD, which will be mentioned later, may imply a protective role of non-steroidal anti-inflammatory drugs (NSAIDs), since NSAIDs are widely used in arthritis patients.

In summary, among the many factors associated with AD, a strong family history of dementia is a risk factor for AD, even though the majority of AD is of non-familial form. Education, arthritis and smoking have been found to reduce the risk of AD.

SHOULD NSAIDS BE USED TO PREVENT AD IN HIGH RISK SUBJECTS?

A significant inverse association of anti-inflammatory drugs (NSAIDs and corticosteroids) and AD was recently reported in a preliminary co-twin control study (10). Following this report, at least two articles have been published in support of the possible protective roles of NSAIDs in AD (11, 38). Earlier evidence in support of an inverse relationship between anti-inflammatory drugs and AD included the low prevalence of AD among patients with arthritis (9, 39), as mentioned earlier. Jenkinson *et al.* (39) reported that only two cases of rheumatoid arthritis cases were found in 96 patients with AD senile dementia, while 12 rheumatoid arthritis cases were found in the same number of controls. The subjects in this study were all aged over 65 years. The relative risk for AD in NSAID users was estimated to be 0.38 compared with all non-users (11). The protective effects of NSAIDs for AD as well as on the cognitive impairment of patients clinically diagnosed with AD (38) suggest that these medications may serve as important interventions to prevent or delay the onset of AD in people who are in high risk groups.

1. Rationale for using anti-inflammatory drugs

Recent evidence has indicated that activation of inflammatory and immune mechanisms accompanies the degenerative process of AD. A characteristic histological hallmark of AD is the presence of senile plaques, consisting of degenerating neurites and amyloid plaques in the brain. A complement-mediated inflammatory response has been reported at both diffuse amyloid plaques and degenerating neurites in AD brains (40-42). This was suggested to represent an early stage in plaque development (41). These acute inflammatory changes are proposed to result in the development of AD pathology or they may be the result of the degenerative process (43). One major component of senile plaque is amyloid b protein, a proteolytic fragment of amyloid precursor protein (APP) (41, 44). It was suggested that APP itself may be an acute phase protein, a normal serum protein whose expression is dramatically influenced by interleukin-1 (IL-1) and interleukin-6 (IL-6) during acute phase response to inflammatory activity (45). As primary mediators of the acute phase response, cytokines, such as IL-1, IL-6 and tumor necrosis factor, have been implicated as being involved in the pathophysiology of AD (46, 47).

Chronic inflammatory reactions, such as the accumulation of reactive microglia, which are the predominant inflammatory cell population in the central nervous system, have been observed in senile plaques (41, 48). These microglia are antigen-presenting cells which express class II major histocompatibility antigen HLA-DR (49, 50). Microglia have demonstrated

immunoreactivity to IL-1 and tumor necrosis factor (50).

The presence of acute phase proteins, cytokines, complement and microglia in amyloid plaque, which are usually seen during the immune response, suggests that inflammatory processes might be responsible for the pathophysiology of AD. Based on this theory, therapeutic intervention with anti-inflammatory drugs should alter or slow down the neurodegenerative process in AD.

2. Potential impact of NSAIDs on AD

Because no curative treatment for AD is available at the present, the potential use of NSAIDs in preventing or delaying the development of AD could become a useful intervention for populations at high risk, such as individuals with a strong family history of AD. Preventive use of NSAIDs in these high risk individuals might reduce the prevalence of AD when these individuals enter elderly age (80 years or over). Let us assume that Andersen's (11) relative risk of 0.38 for AD in NSAIDs users compared with non-users could be applied to the Canadian population. By using NSAIDs as a preventive intervention, the prevalence of AD could be reduced to 1.5% in those aged 65 and over, compared with the prevalence of 5.1% of AD in the same population group without the intervention (2). Indeed, sustained use of NSAIDs was reported recently to be associated with delayed onset and reduced risk of AD among siblings at high risk of AD (51).

3. Future studies

Early studies attempting to establish the preventive role of NSAIDs in AD were mainly using retrospective methods (11). Even in cohort studies, population samples consisted of patients who were clinically diagnosed as having probable AD (38). To evaluate the protective effects of NSAIDs in high risk groups, prospective cohort studies will provide stronger evidence from which to draw a conclusion. The first step in the evaluation process is to identify subjects with a strong family history of AD. Because familial AD has the tendency of early onset, these individuals have a high risk to develop AD by age 50. Therefore, it is ideal to follow these individuals before they reach age 50. The second step is to randomly divide the subjects into two groups, the treatment group who will be given NSAIDs as a preventive measure and the non-treatment group who will receive placebo treatment. Alternatively, the treatment group could be the subjects who are willing to take NSAIDs and the non-treatment group are those who are not willing to take NSAIDs. The cognitive functions of the two groups could be assessed blindly over the years by a specialist. A significantly lower incidence rate of AD in the NSAIDs treatment group compared to the non-treatment group would support a preventive role for NSAIDs in the development of AD. Although it would take some time before the preventive role of

NSAIDs could be confirmed by such cohort study, the potential protective role of NSAIDs could at least provide individuals at high risk some hope or a choice in controlling the quality of their future life.

4. Cautions with NSAIDs

As a prophylactic measure to prevent AD or delay the progress of AD, chronic administration of medication would be required. Although NSAIDs have fewer systemic toxic effects than corticosteroids, the known adverse effects of NSAIDs are still serious drawbacks for routine use of these drugs as a prophylactic measure.

Gastrointestinal side effects, such as gastric upset, abdominal pain, gastrointestinal hemorrhage and pancreatitis have been well documented for NSAIDs use. NSAIDs can also cause serious renal dysfunction. Acute renal failure in children (52) and acute interstitial nephritis (53), as well chronic renal insufficiency (53) have been reported with NSAID use.

It is important to consider the pros and cons of NSAID use to prevent AD in potential AD patients. It is therefore necessary to examine the risk factors related to each individual. As suggested in this paper, only populations at high risk should be considered as candidates in using these drugs as preventive means. The severe adverse effects of NSAIDs on gastrointestinal and renal function dictate that periodic follow up for chronic NSAID users.

CONCLUSION

AD is a progressive neurodegenerative disease. The main interventions at the present are palliative management. Only recently has the inflammatory pathophysiology of AD been revealed by cellular and molecular studies. From the emerging studies of the past five years regarding NSAIDs and AD, we may soon understand the mechanisms by which NSAIDs prevent AD progression.

REFERENCES

1. Statistics Canada 1991 census.
2. Canadian study of health and aging: study methods and the prevalence of dementia *Can Med Assoc J* 1994;150:899-913.
3. Jorm AF. Disability in dementia: assessment, prevention and rehabilitation. *Disabil Rehabil* 1994;16:98-109.
4. Ott A, Breteler MM, van Harskamp F *et al*. Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. *BMJ* 1995;310:970-973.
5. Hasselkus BR. The meaning of activity: day care for persons with Alzheimer disease. *Am J Occup Ther* 1992;46:199-206.
6. Clark RF and Goate AM. Molecular genetics of Alzheimer's disease. *Arch Neurol* 1993;50:1164-1172.
7. Mullan M and Crawford F. Genetic and molecular advances in Alzheimer's disease. *Trends in Neurosci* 1993;10:398-403.
8. Nee L, Polinsky RJ, Eldridge R *et al*. A family with histologically confirmed Alzheimer's disease. *Arch Neurol* 1993;40:203-208.
9. Li G, Shen YC, Li YT *et al*. A case-control study of Alzheimer's disease in China. *Neurol* 1992;42:1481-1488.
10. Breitner JCS, Gau BA, Welsh KA *et al*. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. *Neurology* 1994;44:227-232.
11. Andersen K, Launer LJ, Ott A *et al*. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam study. *Neurology* 1995;45:1441-1445.
12. Huff FJ, Auerbach J, Chakravarti A *et al*. Risk of dementia in relatives of patients with Alzheimer's disease. *Neurology* 1988;38:786-790.
13. Li G, Silverman JM, Smith CJ *et al*. Age at onset and familial risk in Alzheimer's disease. *Am J Psychiatry* 1995;152:424-430.
14. Van Broeckhoven CL. Molecular genetics of Alzheimer's disease: identification of genes and gene mutation. *Eur Neurol* 1995;35:8-19.
15. Schellenberg GD. Molecular genetics of familial Alzheimer's disease. *Arzneimittelforschung* 1995;45:418-424.
16. Hyman BT, West HL, Rebeck GW *et al*. Quantitative analysis of senile plaques in Alzheimer's disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). *Proc Natl Acad Sci USA* 1995;85:3590.
17. Cooper JK and Mungas D. Risk factor and behavioral differences between vascular and Alzheimer's dementias: the pathway to end stage disease. *J Geriatr Psychiatry Neurol* 1993;6:29-33.
18. Tsai MS, Tangalos EG, Petersen RC *et al*. Apolipoprotein E: risk factor for Alzheimer disease. *Am J Hum Genet* 1994;54:643-649.
19. Frisoni GB, Calabresi L, Geroldi C *et al*. Apolipoprotein E epsilon 4 allele in Alzheimer's disease and vascular dementia. *Dementia* 1994;6:240-242.
20. Rasmusson DX, Brandt J, Martin DB *et al*. Head injury as a risk factor in Alzheimer's disease. *Brain Inj* 1995;9:213-219.
21. Takeshima T, Taniguchi R, Kitagawa T *et al*. Headaches in dementia. *Headache* 1990;30:735-738.
22. van Duijn CM, Havekes LM, Van Broeckhoven C *et al*. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. *BMJ* 1995;310:627-631.
23. Garruto RM. Pacific paradigms of environmentally-induced neurological disorders: clinical, epidemiological and molecular perspectives. *Neurotoxicology* 1991;12:347-377.
24. Wettstel A, Aeppli A, Gautschi K *et al*. Failure to find a relationship between mnemonic skills of octogenarians and aluminum in drinking water. *Int Arch Occup Environ Health* 1991;63:97-103.
25. Forster DP, Newens AJ, Kay DW *et al*. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: a case-control study in Northern England. *J Epidemiol Community Health* 1995;49:253-258.
26. McLachlan DR, Kruck TP, Lukiw WJ *et al*. Would decreased aluminum ingestion reduce the incidence of Alzheimer's disease? *Can Med Assoc J* 1991;145:253-258.
27. Kraus AS and Forbes WF. Aluminum, fluoride and the prevention of Alzheimer's disease. *Can J Public Health* 1992;83:97-100.
28. Zhang M, Katzman R, Salmon D *et al*. The prevalence of dementia and Alzheimer's disease in Shanghai, China: impact of age gender and education. *Ann Neurol* 1990;27:428-437.
29. Friedland RP. Epidemiology, education and the ecology of Alzheimer's disease. *Neurology* 1993;43:246-249.
30. Bonaiuto S, Rocca WA, Lippi A *et al*. Impact of education and occupation on the prevalence of Alzheimer's disease and multi-infarct dementia in Appignano, Macerata Province, Italy. *Neurology* 1990;40:S346.
31. Katzman R. Education and the prevalence of dementia and Alzheimer's disease. *Neurology* 1993;43:13-20.
32. Cobb JL, Wolf PA, Au R *et al*. The effect of education on the incidence of dementia and Alzheimer's disease in the Framingham study. *Neurology* 1995;45:1707-1712.
33. Bonaiuto S, Rocca WA, Lippi A *et al*. Education and occupation as risk factors for dementia: a population-based case-control study. *Neuroepidemiology* 1995;14:101-109.
34. Breteler MMB, Claus JJ, Duijn CM *et al*. Epidemiology of Alzheimer's disease. *Epidemiol Rev* 1992;14:59-82.

35. Marder T, Tang MX, Cote *et al.* The frequency and associated risk factors for dementia in patients with Parkinson's disease. *Arch Neurology* 1995;52:695-701.
36. Whitehouse PJ and Kalaria RN. Nicotinic receptors and neurodegenerative dementing diseases: basic research and clinical implications. *Alzheimer Dis Assoc Discord* 1995; (Suppl 2):3-5.
37. Brenner DE, Kukull WA, van Belle G *et al.* Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. *Neurology* 1993;43:293-300.
38. Rich JB, Rasmusson DX, Folstein MF *et al.* Non-steroidal anti-inflammatory drugs in Alzheimer's disease. *Neurology* 1995;45:51-55.
39. Jenkinson ML, Bliss MR, Brain AT *et al.* Rheumatoid arthritis and senile dementia of the Alzheimer's type. *Br J Rheumatol* 1989;28:86-88.
40. Eikelenboom P, Hack CE, Rozenmuller JM *et al.* Complement activation in amyloid plaques in Alzheimer's dementia. *Virchow's Arch B Cell Pathol* 1989;56:259-262.
41. Eikelenboom P, Zhan SS, van Gool WA *et al.* Inflammatory mechanisms in Alzheimer's disease. *Trends Pharmacol Sci* 1994;7:299-304.
42. McGeer PL, Akiyama H, Itagaki S *et al.* Activation of the classic complement pathway in brain tissue of Alzheimer patients. *Neurosci Lett* 1989;107:341-346.
43. Bradford F, Foly P, Docherty M *et al.* Antibodies in serum of patients with Alzheimer's disease cause immunolysis of cholinergic nerve terminals from the rat cerebral cortex. *Can J Neurol Sci* 1989;16:528-534.
44. Kang J, Lemaire HG, Unterbeck A *et al.* The precursor of Alzheimer's disease amyloid A4 protein resembles a cell surface receptor. *Nature* 1987;325:733-736.
45. Vandenabeele P and Fiers W. Is amyloidogenesis during Alzheimer's disease due to an IL-1/IL-6-mediated "acute phase response" in the brain? *Immunol Today* 1991;12:217-219.
46. Moshage HJ, Roelofs HMJ, van Pelt JF *et al.* The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of human hepatocytes. *Biochem Biophys Res Commun* 1988;155:112-117.
47. Fillit H, Ding W, Buee L *et al.* Elevated circulating tumor necrosis factor levels in Alzheimer's disease. *Neurosci Lett* 1991;129:318-320.
48. McGeer PL, Akiyama H, Itagaki S *et al.* Immune system response in Alzheimer's disease. *Can J Neurol Sci* 1989;16:516-527.
49. Perlmutter LS, Scott SA, Barron E *et al.* MHC class II-positive microglia in human brain: association with Alzheimer's lesions. *J Neurosci Res* 1992;33:549-558.
50. Dickson DW, Lee SC, Mattiace LA *et al.* Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease. *Glia* 1993;7:75-83.
51. Breitner JC, Welsh KA, Helms MJ *et al.* Delayed onset of Alzheimer's disease with non-steroidal anti-inflammatory and histamine H2 blocking drugs. *Neurobiol Aging* 1995;16:523-530.
52. Lantz B, Cochat P, Bouchet JL *et al.* Short-term niflumic acid-induced acute renal failure in children. *Nephrol Dial Transplant* 1994;9:1234-1239.
53. Kleinknecht D. Interstitial nephritis, the nephrotic syndrome and chronic renal failure secondary to non-steroidal anti-inflammatory drugs. *Semin Nephrol* 1995;15:228-235.
54. Speck CE, Kukull WA, Brenner DE *et al.* History of depression as a risk factor for Alzheimer's disease. *Epidemiology* 1995;6:366-369.
55. Sutherland MK, Wong L, Somerville MJ *et al.* Reduction of thyroid hormone receptor c-ERBA alpha mRNA levels in the hippocampus of Alzheimer as compared to Huntington brain. *Neurobiol Aging* 1992;13:301-312.

Canada's foremost medical and pharmaceutical healthcare communications operation anticipates readers and advertisers needs with a standard-setting collection of titles:

The Medical Post
 The Nutrition Post
 Canadian Healthcare Manager
 Prix Galien
 The National Survey
 L'Actualité Médicale



Family Practice
 Patient Care
 L'Omnipraticien
 Pharmacy Practice
 Hospital Pharmacy Practice
 Pharmacy Post
 L'Actualité Pharmaceutique